BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 24148817)

  • 1. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.
    Reid G; Pel ME; Kirschner MB; Cheng YY; Mugridge N; Weiss J; Williams M; Wright C; Edelman JJ; Vallely MP; McCaughan BC; Klebe S; Brahmbhatt H; MacDiarmid JA; van Zandwijk N
    Ann Oncol; 2013 Dec; 24(12):3128-35. PubMed ID: 24148817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma.
    Cioce M; Ganci F; Canu V; Sacconi A; Mori F; Canino C; Korita E; Casini B; Alessandrini G; Cambria A; Carosi MA; Blandino R; Panebianco V; Facciolo F; Visca P; Volinia S; Muti P; Strano S; Croce CM; Pass HI; Blandino G
    Oncogene; 2014 Nov; 33(46):5319-31. PubMed ID: 24240684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma.
    Williams M; Kirschner MB; Cheng YY; Hanh J; Weiss J; Mugridge N; Wright CM; Linton A; Kao SC; Edelman JJ; Vallely MP; McCaughan BC; Cooper W; Klebe S; Lin RC; Brahmbhatt H; MacDiarmid J; van Zandwijk N; Reid G
    Oncotarget; 2015 Sep; 6(27):23480-95. PubMed ID: 26125439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma.
    Yamamoto K; Seike M; Takeuchi S; Soeno C; Miyanaga A; Noro R; Minegishi Y; Kubota K; Gemma A
    Oncol Rep; 2014 Dec; 32(6):2365-72. PubMed ID: 25231602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma.
    Johnson TG; Schelch K; Cheng YY; Williams M; Sarun KH; Kirschner MB; Kao S; Linton A; Klebe S; McCaughan BC; Lin RCY; Pirker C; Berger W; Lasham A; van Zandwijk N; Reid G
    J Thorac Oncol; 2018 Feb; 13(2):258-272. PubMed ID: 29113949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines.
    Nagai S; Takenaka K; Sonobe M; Wada H; Tanaka F
    Chemotherapy; 2008; 54(3):166-75. PubMed ID: 18560222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
    Kao SC; Cheng YY; Williams M; Kirschner MB; Madore J; Lum T; Sarun KH; Linton A; McCaughan B; Klebe S; van Zandwijk N; Scolyer RA; Boyer MJ; Cooper WA; Reid G
    J Thorac Oncol; 2017 Sep; 12(9):1421-1433. PubMed ID: 28629895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.
    Cheng YY; Wright CM; Kirschner MB; Williams M; Sarun KH; Sytnyk V; Leshchynska I; Edelman JJ; Vallely MP; McCaughan BC; Klebe S; van Zandwijk N; Lin RC; Reid G
    Mol Cancer; 2016 Jun; 15(1):44. PubMed ID: 27245839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.
    Cheng YY; Kirschner MB; Cheng NC; Gattani S; Klebe S; Edelman JJ; Vallely MP; McCaughan BC; Jin HC; van Zandwijk N; Reid G
    J Thorac Oncol; 2013 Oct; 8(10):1317-28. PubMed ID: 24457242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
    Laszlo V; Hoda MA; Garay T; Pirker C; Ghanim B; Klikovits T; Dong YW; Rozsas A; Kenessey I; Szirtes I; Grusch M; Jakopovic M; Samarzija M; Brcic L; Kern I; Rozman A; Popper H; Zöchbauer-Müller S; Heller G; Altenberger C; Ziegler B; Klepetko W; Berger W; Dome B; Hegedus B
    J Pathol; 2015 Oct; 237(2):203-14. PubMed ID: 26011651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma.
    Schelch K; Kirschner MB; Williams M; Cheng YY; van Zandwijk N; Grusch M; Reid G
    Mol Oncol; 2018 Jan; 12(1):58-73. PubMed ID: 29094504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
    Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
    J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
    You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
    J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma.
    Andersen M; Trapani D; Ravn J; Sørensen JB; Andersen CB; Grauslund M; Santoni-Rugiu E
    Anticancer Res; 2015 Nov; 35(11):6223-9. PubMed ID: 26504055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-1 induces growth arrest and apoptosis in malignant mesothelioma.
    Xu Y; Zheng M; Merritt RE; Shrager JB; Wakelee HA; Kratzke RA; Hoang CD
    Chest; 2013 Nov; 144(5):1632-1643. PubMed ID: 23828229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
    Villanova T; Gesmundo I; Audrito V; Vitale N; Silvagno F; Musuraca C; Righi L; Libener R; Riganti C; Bironzo P; Deaglio S; Papotti M; Cai R; Sha W; Ghigo E; Schally AV; Granata R
    Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2226-2231. PubMed ID: 30659154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma.
    Iwahori K; Serada S; Fujimoto M; Ripley B; Nomura S; Mizuguchi H; Shimada K; Takahashi T; Kawase I; Kishimoto T; Naka T
    Int J Cancer; 2013 Jan; 132(2):459-71. PubMed ID: 22532243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.
    Cortes-Dericks L; Carboni GL; Schmid RA; Karoubi G
    Int J Oncol; 2010 Aug; 37(2):437-44. PubMed ID: 20596671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-215-5p Treatment Suppresses Mesothelioma Progression via the MDM2-p53-Signaling Axis.
    Singh A; Bhattacharyya N; Srivastava A; Pruett N; Ripley RT; Schrump DS; Hoang CD
    Mol Ther; 2019 Sep; 27(9):1665-1680. PubMed ID: 31227395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
    Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
    Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.